Last updated: July 6, 2026
ISOVUE-128 (iopamidol) fundamentals and investment outlook: patents, FDA status, competitive risks, and revenue exposure
ISOVUE-128 (iopamidol 61% iodine/mL; 128 mg iodine/mL class) is an iodinated contrast media product in the high-volume hospital imaging segment. The investment case is driven by (1) supply reliability and GMP/sterility performance, (2) competitive pricing versus other branded and AB-rated generics, (3) payer and IDN contracting, and (4) the legal strength of any remaining formulation, packaging, and method-of-use patent coverage. Downside risks concentrate in generic erosion, margin compression, and litigation or FDA manufacturing actions tied to sterile injectable products.
Because ISOVUE-128 is an established small-molecule contrast agent, near-term exclusivity is generally not the dominant value lever compared with manufacturing execution and competitive market dynamics. Your outcome as an investor hinges on whether you underwrite continued brand defensibility (patents, 505(b)(2) exclusivities, and labeling differentiation) versus generic price-led substitution.
What is ISOVUE-128 and where does it make money?
ISOVUE-128 is an iodinated contrast medium (iopamidol) used in diagnostic imaging. It is administered intravenously for enhanced imaging in CT and other imaging modalities, and it competes within the broader class of nonionic, low-osmolar iodinated contrast agents.
Core commercial characteristics investors should underwrite
- Setting: hospital outpatient imaging and inpatient radiology.
- Procurement dynamic: IDN group purchasing, distributor pricing, and tender-based contracting.
- Usage: high unit volume, sensitive to imaging utilization trends and substitution between contrast agents.
- Adverse event-driven protocols: premedication and renal monitoring pathways affect switching friction.
Revenue driver map (high-level)
- Imaging volume (CT utilization).
- Patient mix (contrast dose distribution changes with protocol).
- Contract price (tender outcomes and formulary inclusion).
- Product availability and fill-rate reliability.
What patents protect ISOVUE-128 (iopamidol 128 mg iodine/mL)?
ISOVUE-128 patent defense typically relies on secondary IP around specific formulations, manufacturing controls, and packaging, rather than on composition-of-matter for iopamidol itself. For an investment underwriting model, the critical work is to map the Orange Book–listed patents for the exact NDC(s) corresponding to ISOVUE-128 and then test each for expiration timing and litigation status.
Patent estate assessment framework for contrast media
- Composition of matter: usually long expired for legacy iodinated agents.
- Formulation patents: may cover concentration, excipient system, osmolality targets, or stability improvements.
- Method-of-use patents: may attempt to cover dosing protocols, imaging procedures, or patient subsets.
- Manufacturing/process patents: sterile filtration, aseptic processing, or specific batch release criteria.
- Packaging patents: device/container closure systems and extractables/leachables controls.
Investment implication
If ISOVUE-128 has limited remaining, enforceable, Orange Book-listed claims for the listed NDC(s), the investment case compresses into operational execution and contracting. If there is meaningful remaining patent life for a specific presentation (container size, delivery configuration), that can slow substitution and preserve margin through the claim expiry window.
(Note: This response does not include an itemized patent table because complete, NDC-specific Orange Book data is not provided in the prompt.)
When does ISOVUE-128 lose exclusivity?
Exclusivity timing for ISOVUE-128 is usually driven by Orange Book patent expirations and any data exclusivity associated with the NDA/NDA supplement history, not by a single “market exclusivity” event. For investment models, the key input is the remaining patent term per NDC and the last day to file a Paragraph IV (if any ANDA is pending) or to launch for an AB-rated generic (if patents expire).
What matters to a launch timeline
- Patent-by-patent expiration dates for each NDC strength (including package size variants).
- PTE/PTE-adjusted dates (if any) affecting regulatory patent term.
- Any listed patents that are “delisted” vs actively asserted.
- Whether the active ingredient and route are the same across competing ANDAs.
(No exclusivity calendar is produced here because NDC-specific Orange Book entries are not provided.)
How many ANDA/generic competitors exist for ISOVUE-128 and what is the generic entry risk?
Generic entry risk is structurally high for iodinated contrast products because the active ingredient is mature and substitution is common when pricing gaps widen. The practical question is whether generic competitors have (a) an approved ANDA, (b) a launch-ready product that meets hospital tolerability and protocol expectations, and (c) a path around any remaining patent coverage.
Generic entry triggers investors track
- ANDA approvals tied to specific NDCs matching the concentration and route.
- Paragraph IV litigation that may delay launch.
- Patent “carve-out” strategies in settlements (entry dates tied to specific NDCs).
- Wholesale/distributor availability and demand capture after first tender wins.
What “entry” looks like in hospitals
- Contracting shifts are often “sweep-based,” where purchasing groups convert to a lower-cost alternative across multiple sites.
- Tender cycles drive lagged adoption even after regulatory approval.
What Orange Book status does ISOVUE-128 have?
ISOVUE-128’s Orange Book status determines the enforceability window for any remaining patents and the leverage for generic challengers. For contrast media, investors typically use Orange Book status to map:
- which listed patents are still active,
- which are earliest-to-expire,
- and which are the most likely to be asserted in litigation.
(No Orange Book table is included because the prompt does not provide NDC or Orange Book listing data.)
What patent litigation affects ISOVUE-128 and how do settlements change launch timing?
In iodinated contrast markets, litigation typically shapes:
- launch design (which NDCs are authorized),
- entry timing (carve-out dates),
- and the scope of “at-risk” launch.
Settlement and risk modeling inputs
- Carve-out by strength, container size, or distribution channel.
- “Automatic” forfeiture or stipulation terms that trigger later entry.
- Cofirm relationships and authorized distributor commitments.
(No specific litigation history is provided in the prompt; therefore no case-level timeline is listed.)
How does ISOVUE-128 compare with other iodinated contrast agents (pricing and competitive dynamics)?
ISOVUE-128 competes in the broader iodinated contrast portfolio across:
- other iopamidol strengths and presentations,
- ioversol, iohexol, iodixanol, and related nonionic agents.
Competitive factors investors should underwrite
- Therapeutic interchangeability in practice: radiology protocols often allow substitution, subject to institutional preference.
- Renal safety perception: despite similar risk classes, hospital formularies often differ based on historical experience.
- Supply reliability: contrast media shortages have historically triggered emergency procurement and temporary price premiums.
Investment implication
In a mature class, the “brand” premium is often temporary and contract-bound. A strong underwriting model assumes generic pressure unless evidence shows:
- durable patent coverage mapped to NDC-specific claims, or
- unique product attributes that limit substitution (rare in this class).
What formulation and manufacturing IP barriers exist for ISOVUE-128?
For injectable sterile contrast products, manufacturing IP and quality systems often matter more than composition claims.
Barriers investors should treat as material
- Sterile filtration and aseptic processing controls
- Container closure integrity
- Stability during distribution
- Batch release specifications and acceptance criteria
- Extractables/leachables controls for the specific container system
Why this affects investment outcomes
- Manufacturing disruptions can halt shipments and create contract penalties.
- Tight QA reduces switching to new suppliers due to procurement caution after incidents.
What FDA status applies to ISOVUE-128 (NDA/ANDA, approvals, labeling)?
FDA regulatory status for ISOVUE-128 is a function of its NDA history and the presence of generic ANDA approvals for matching NDCs. The relevant investment inputs are:
- whether the product is a listed NDA with multiple NDC strengths,
- whether competitors have AB-rated status,
- and whether label differentiation limits interchangeability.
(No specific NDA/ANDA identifiers, approval dates, or labeling references are available in the prompt, so no regulatory timeline is produced.)
How does the ISOVUE-128 supply chain affect investment fundamentals?
In high-volume contrast agents, supply reliability can determine quarterly revenue more than IP.
Supply chain issues investors should monitor
- Filtration/sterile manufacturing deviations leading to holds.
- Raw material sourcing concentration.
- Packaging component availability.
- Distributor constraints and allocation.
Market behavior during shortages
- Hospitals may temporarily accept higher pricing or alternate SKUs.
- When supply normalizes, price discounts and tender-based switching resume quickly.
What is the investment bull case vs bear case for ISOVUE-128?
Bull case (data-driven themes)
- Remaining, enforceable Orange Book patents tied to specific NDCs limit full generic substitution through the next contract cycles.
- Strong hospital tender performance sustains formulary share despite price pressure.
- Supply execution prevents stock-outs, preserving revenue and avoiding costly reinstatement after disruptions.
Bear case (primary downside pathways)
- Early and broad AB-rated generic availability compresses net pricing.
- Delisting or limited patent coverage leaves launch unblocked, accelerating substitution.
- Manufacturing quality events cause shipment delays, leading to demand loss and reputational procurement tightening.
Key underwriting checklist for an investment model
Use this structure to translate patent and regulatory realities into a revenue-and-margin forecast:
- NDC-by-NDC patent term map
- earliest expiry,
- which patents are actively asserted (if any),
- and whether carve-outs exist.
- Competition map
- confirmed ANDA approvals for matching NDCs,
- expected launch dates from litigation or settlement terms.
- Pricing and contracting
- tender cadence for your target customer base,
- typical gross-to-net behavior during generic pressure.
- Supply reliability
- recent inspection outcomes and deviation history,
- production capacity resilience and lead times.
Key Takeaways
- ISOVUE-128’s investment fundamentals depend primarily on hospital contracting and supply reliability, with patent strength acting as a gating factor for how long price erosion can be delayed.
- For iodinated contrast media, composition-of-matter defensibility is usually not the main value driver; NDC-specific Orange Book patents (formulation, process, packaging, and sometimes method-of-use) are.
- Generic entry risk is structurally high; the investment question is how much remaining, enforceable patent coverage exists for the exact NDCs and whether litigation/settlements create timed entry carve-outs.
- A robust model should be built around NDC-specific patent expirations, competitor ANDA status, tender cycle timing, and GMP stability.
FAQs
1) What NDCs define ISOVUE-128’s patent exposure?
ISOVUE-128’s enforceability and generic substitution timeline must be modeled by its specific NDC presentations (container size/strength/route). Without NDC-level mapping, exclusivity and entry risk can be misread.
2) Are method-of-use patents likely to matter for iodinated contrast imaging?
Method-of-use claims can matter if they are specific to identifiable imaging protocols or dosing regimens that are tightly used in real-world practice and if they remain enforceable. In mature contrast classes, they are less common than formulation and process protections.
3) How do Paragraph IV filings change the generic launch calendar for ISOVUE-128?
Paragraph IV certifications can trigger 30-month stays and litigation-driven settlement carve-outs that shift launch timing by strength or NDC, often delaying price erosion relative to “regulatory approval only” scenarios.
4) What quality events most often disrupt iodinated contrast media revenue?
Aseptic processing failures, sterile filtration deviations, and container closure integrity issues can lead to manufacturing holds and lost shipments, creating revenue volatility even without patent-related changes.
5) What competitive strategy typically works in iodinated contrast contracting?
Winning relies on consistent supply, reliable reimbursement and wholesaler alignment, and tender pricing that anticipates generic ramp after regulatory approval or settlement-driven entry.
References
No sources were cited because the prompt did not provide ISOVUE-128 NDC-specific Orange Book, litigation, or FDA application identifiers necessary to produce an accurate patent and regulatory record.
